Bluebird Bio Competitors and Similar CompaniesClear all
Tanvex BioPharma's competitors and similar companies include G1 Therapeutics, Ionis Pharmaceuticals, Genprex and Bellicum Pharmaceuticals.
 Tanvex BioPharma Tanvex BioPharma (formerly known as Ruenvex Biotech) is a company that manufactures and develops biosimilar and biologic products and drugs. |  G1 Therapeutics G1 Therapeutics is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. |  Ionis Pharmaceuticals Ionis Pharmaceuticals (formerly known as Isis Pharmaceuticals) is a company that discovers and develops RNA-targeted therapeutics. |  Bellicum Pharmaceuticals Bellicum Pharmaceuticals is a biopharmaceutical company focused on discovering and developing cellular immunotherapies. | ||
Founding Date | Founding Date 2013 | Founding Date 2008 | Founding Date 1989 | Founding Date 2009 | Founding Date 2004 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Taipei, TW HQ New Taipei, TW Irvine, US San Diego, US San Diego, US | Locations Durham, US HQ | Locations Carlsbad, US HQ | Locations West Lake Hills, US HQ Austin, US | Locations Houston, US HQ Houston, US Houston, US South San Francisco, US |
Employees | Employees 13827% decrease | Employees 17015% increase | Employees 92716% increase | Employees 2865% increase | Employees 1386% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) 377.2 m | Valuation ($) 6.3 b | Valuation ($) 6.3 m | Valuation ($) 778.3 k |
Financial | |||||
Revenue (est.) | Revenue (est.) NT$34.7m (FY, 2024) | Revenue (est.) $82.5m (FY, 2023) | Revenue (est.) $705.1m (FY, 2024) | Revenue (est.) N/A | Revenue (est.) $1.5m (FY, 2022) |
Cost of goods | Cost of goods NT$26.4m (FY, 2024) | Cost of goods N/A | Cost of goods $11.2m (FY, 2024) | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit NT$8.7m (FY, 2024) | Gross profit N/A | Gross profit $693.9m (FY, 2024) | Gross profit N/A | Gross profit N/A |
Net income | Net income (NT$1.4b) (FY, 2024) | Net income ($48m) (FY, 2023) | Net income ($453.9m) (FY, 2024) | Net income ($21.1m) (FY, 2024) | Net income ($25m) (FY, 2022) |
Funding | |||||
Total funding raised | Total funding raised $ 346.9m | Total funding raised $ 289.6m | Total funding raised N/A | Total funding raised N/A | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
G1 Therapeutics
HQ
Durham, US
Employees
170↑ 15% increase
G1 Therapeutics is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer.
View companyIonis Pharmaceuticals
HQ
Carlsbad, US
Employees
927↑ 16% increase
Ionis Pharmaceuticals (formerly known as Isis Pharmaceuticals) is a company that discovers and develops RNA-targeted therapeutics.
View company
Genprex
HQ
West Lake Hills, US
Employees
28
Genprex is a gene therapy company developing treatments for cancer and diabetes.
View companyBellicum Pharmaceuticals
HQ
Houston, US
Employees
13
Bellicum Pharmaceuticals is a biopharmaceutical company focused on discovering and developing cellular immunotherapies.
View company